Invion Limited

IVX

AU000000IVX4

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 01:21:25 2024-05-16 am EDT			5-day change	1st Jan Change
0.0055 ^AUD	+10.00%		+10.00%	+10.00%

May. 08	Invion Partners with Hanlim Pharma for Glioblastoma Treatment	MT
Mar. 05	Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results	MT

Invion Limited Announces the Appointment of Craig Newton as Director Effective from 4 November 2019

November 03, 2019 at 08:20 pm EST

Invion Limited announced the appointment of Craig Newton as director effective from 4 November 2019.

Latest news about Invion Limited

Invion Partners with Hanlim Pharma for Glioblastoma Treatment	May. 07	MT
Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results	Mar. 05	MT
Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Invion Signs Collaboration Agreement with Dr. I&B Co for HPV Treatment; Shares Up 25%	Feb. 22	MT
Invion Nears Clinical Trial of Cancer Photodynamic Therapy with Drug Substance Production	Nov. 21	MT
Invion Grants RMW Cho Group Right to Distribute Cancer Treatment Products in South Korea	23-09-26	MT
Invion Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Invion Launches New Interactive Investor Hub	23-04-10	MT
Invion Limited agreed to acquire Next Generation Photodynamic Therapy of RMW Cho Group Limited.	23-04-05	CI
Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-22	CI
Invion Expanding Photosoft Technology Rights to US, Canada, Hong Kong	23-02-08	MT
Invion Limited Announces Vitro Test Results on Photosoft	22-10-25	CI
Invion Limited Announces the Positive Screening Results from in Vitro Studies of PhotosoftTM on the Inhibition of the Dengue Virus	22-10-24	CI
Invion Validates Efficacy of Photodynamic Drug Against Anal Cancer	22-09-15	MT
Invion Limited Announces INV043 Effective Against Anal Cancer Squamous Cell Carcinomas in Vitro	22-09-14	CI
Invion Limited Announces PhotosoftTM Shows Activity Against Zika Virus in Preliminary Assays	22-09-07	CI
Invion Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-17	CI
Invion's Cancer Treatment Patent Application Published	22-06-09	MT
Invion Limited Announces International Patent to Extend IP Protection for Photosoft	22-06-07	CI
Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-22	CI
Invion Limited Announces Company Secretary Changes	21-10-28	CI
Invion's Cancer Drug Regresses Tumor, Triggers Immune Response in Animal Study; Shares Surge 131%	21-10-27	MT
Invion Limited Announces INV043 Shown to Completely Regress TNBC Tumours and Trigger Protective Immunity	21-10-27	CI
Invion Limited Reports Earnings Results for the Full Year Ended June 30, 2021	21-08-04	CI
Invion Limited Auditor Raises 'Going Concern' Doubt	21-08-03	CI

Invion Limited is an Australia-based life sciences company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is engaged in the clinical development of a PhotoDynamic Therapy (PDT) for cancer. Its photosensitizer (the agent used in PDT) is called IVX-PDT and is based on Photosoft Technology. Its PDT is an alternative to surgery, and in contrast to radiotherapy and chemotherapy, which are immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumor by leukocytes. It produces topical and intravenous products suitable for use in skin cancer and in solid tumors, such as those present in ovarian, prostate and lung cancer. It is developing a topical formulation of its photosensitizing agent, IVX-PDT, to treat superficial Basal Cell Carcinoma (sBCC), Actinic Keratosis (AK) and Squamous Cell Cancer (SCC).

Sector

Biotechnology & Medical Research

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INVION LIMITED	+10.00%	21.47M
MODERNA, INC.	+33.03%	49.46B
IQVIA HOLDINGS INC.	+1.41%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.70%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.68%	18.64B
BIO-TECHNE CORPORATION	+8.35%	13.16B
MEDPACE HOLDINGS, INC.	+29.30%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.30%	12.1B

Other Biotechnology & Medical Research

Invion Limited

Equities

IVX

AU000000IVX4

Biotechnology & Medical Research

Invion Limited Announces the Appointment of Craig Newton as Director Effective from 4 November 2019

Latest news about Invion Limited

Chart Invion Limited

Company Profile

Income Statement Evolution

Sector Other Biotechnology & Medical Research